Tempus AI, Inc

Equities

TEM

US88023B1035

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-22 EDT 5-day change 1st Jan Change
42.98 USD +3.82% Intraday chart for Tempus AI, Inc +17.43% 0.00%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Tempus AI, Inc. Expands Immuno-Oncology Portfolio with Launch of AI-Enabled, Multimodal Immune Profile Algorithmic Tests CI
Wall Street analysts bullish on genetic testing firm Tempus AI RE
Nasdaq and S&P 500 hit records, fueled by Nvidia RE
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Tempus AI Poised for 27% Topline Growth Through 2028, Morgan Stanley Says MT
Chip stocks, megacaps steer S&P 500, Nasdaq to record highs RE
Wall Street analysts bullish on genetic testing firm Tempus AI RE
BofA Securities Starts Tempus AI With Buy Rating, $41 Price Target MT
TD Cowen Initiates Tempus AI at Buy With $50 Price Target MT
Loop Capital Initiates Tempus AI at Buy With $48 Price Target MT
William Blair Initiates Tempus AI at Outperform MT
JPMorgan Initiates Tempus AI at Overweight With $42 Price Target MT
Stifel Initiates Tempus AI at Buy With $45 Price Target MT
Needham Initiates Tempus AI at Buy With $47 Price Target MT
Morgan Stanley Initiates Tempus AI at Overweight With $44 Price Target MT
Futures higher as megacaps, chip stocks rise ahead of Powell comments RE
Tempus AI, Inc Announces American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurlSTSM CI
Tempus AI Gets Advanced Diagnostic Laboratory Test Status For Sequencing Test From CMS MT
CMS Awards Tempus AI, Inc. with Advanced Diagnostic Laboratory Test Status for its xT CDx Test CI
Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut RE
SoftBank Group to Form Joint Venture with Tempus AI CI
SoftBank Group to Form Joint Venture With U.S. Healthcare Firm Tempus AI DJ
SoftBank Group launches AI healthcare joint venture with Tempus AI RE
Tempus AI's Atrial Fibrillation Risk Detection Device Gets FDA Clearance MT
Tempus AI Gets 510(k) Clearance for ECG-AF Device DJ
Chart Tempus AI, Inc
More charts
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
41.4 USD
Average target price
46 USD
Spread / Average Target
+11.11%
Consensus
  1. Stock Market
  2. Equities
  3. TEM Stock
  4. News Tempus AI, Inc
  5. Tempus AI Shares Rise Above IPO Price in Nasdaq Debut